Markets
markets

Pfizer to buy obesity drug developer Metsera for up to $7.3 billion

Pfizer rose in premarket trading after it announced that it would acquire anti-obesity drug developer Metsera, which puts the pharmaceutical giant back in the weight-loss medication game after its own pill didn’t advance to the final stages of trials.

The transaction is a valued at $47.50 per share (roughly $4.9 billion by enterprise value), which could rise to $70 per share (or $7.3 billion) if certain clinical and regulatory milestones are met. Metsera closed at $33.32 on Friday and shot up nearly 60% in premarket trading.

The deal, which was paid for with a combination of cash and debt, is expected to close by the end of the year.

Metsera is developing a weight-loss shot (called MET-233i) that has shown promise but is still in early trials, meaning it will likely be years before it reaches patients. Notably, the shot is able to be taken monthly rather than weekly like the GLP-1 shots currently on the market made by Eli Lilly and Novo Nordisk.

More Markets

See all Markets
markets

JPMorgan recommends bullish options bet on Micron ahead of earnings

JPMorgan equity derivatives strategists led by Bram Kaplan think Micron is poised to jump after it reports earnings on Tuesday after the close — but not by too too much.

Micron has had an exceptionally hot run lately. Before Friday’s drop, shares of the memory chip specialist enjoyed a record-winning streak buoyed by a bevy of positive newsflow on AI data center spending.

Kaplan says options that encompass the reaction to Micron’s earnings look expensive, as they currently imply a move of +/-9.6% versus an average absolute change of 7.4% over the past three years. And with such an explosive advance over the past few weeks, he reckons the odds of an outsized surge on earnings are not high.

“The company’s pre-announcement should partially de-risk the earnings print, which, along with our analyst’s $185 price target (~14% upside), gives us comfort selling deep upside, leading us to favor call ratios to position into earnings,” he writes.

JPMorgan’s recommendation:

  • Buy one call option on Micron that expires this Friday with a strike price of $170, and

  • Sell two call options on Micron that expire this Friday with a strike price of $180.

This trade doesn’t cost anything in terms of premium; you actually get paid for putting it on. The potential downside is that significant losses could result in the event the stock goes parabolic this week.

The sell side anticipates that Micron will deliver adjusted diluted earnings per share of $2.84 on sales of $11.15 billion and adjusted gross margins of 44.5% in its fiscal fourth-quarter results on Tuesday, per analysts surveyed by Bloomberg.

JPM’s semiconductor analysts think that earnings and margins will exceed expectations, and guidance for the current quarter will also surprise to the upside. Commentary around margins, supply commitments, and the balance of supply and demand for high bandwidth memory chips next year will likely be the key factors that drive the stock amid the release of earnings and the quarterly conference call, in their view.

“Given materially higher high bandwidth memory content for XPUs/GPUs shipped in calendar year 2026 vs. calendar year 2025, and likely upside to current XPU/GPU unit growth expectations for CY26 against a backdrop of rising hyperscaler capex budgets, our analysts see little risk of oversupply next year,” he writes.

Kaplan’s got a hot hand when it comes to trade calls on semiconductor earnings: in early September, his bullish options recommendation on Broadcom ahead of its quarterly report delivered a return in excess of 450% after the AI chip designer unveiled a major new customer later reported to be OpenAI.

markets

Snap surges on positive r/WallStreetBets chatter as users hope for potential acquisition

While Snap initially took a hit on reports that the US and China had reached the framework for an agreement to maintain TikTok’s presence in the US, that news didn’t even keep the stock down for a day.

Indeed, Snap has been on a bit of a tear lately — putting together a six-session winning streak before Friday’s swoon — in which the stock gained nearly 17%. And shares of the social media company are up again big this morning, thanks seemingly in no small part to the retail traders that populate Reddit’s r/WallStreetBets.

SNAP is the ticker with the most mentions (and the most positive mentions) on the subreddit over the last 12 hours, per data from SwaggyStocks, with many users reportedly positioned bullishly via options.

SwaggyStocks top trending on WSB
Source: SwaggyStocks (as of 6:53 a.m. ET 9/22/25)

Five-day average volumes in SNAP have surged to a record high as of Friday, as some users on the subreddit speculate that the beaten-down social media company might make for an attractive acquisition target.

markets

QUBT drops after announcing $500 million at-the-market stock offering

Quantum Computing shares were trading 12% lower early on Monday after the company announced a $500 million at-the-market share offering, a not insignificant amount of dilution for shareholders of the $3.72 billion market cap company (as of Friday’s close).

QUBT plans to use the proceeds from the offering to "accelerate commercialization efforts, strategic acquisitions, expand sales and engineering personnel, working capital, and general corporate purposes," per the press release. The company also noted that the stock offering, which will take place on or about September 24 with institutional investors, has been arranged in an "oversubscribed" private placement.

The announcement marks the company's fifth and biggest stock offering since November 2024, which will bring the total capital raised from the period to some $900 million.

The company’s shares were up more than 20% on Friday following a wave of bullish sentiment and newsflow on the quantum sector.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.